Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).

CPQ neurology and psychology Pub Date : 2018-01-01 Epub Date: 2018-12-04
Blum Kenneth, Modestino J Edward, Gondre Lewis C Marjorie, Baron David, Steinberg Bruce, Thanos K Panayotis, Downs B William, Siwicki Davis, Lott Lisa, Braverman R Eric, Moran Mark, Miller David, Fried Lyle, Badgaiyan D Rajendra
{"title":"Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).","authors":"Blum Kenneth, Modestino J Edward, Gondre Lewis C Marjorie, Baron David, Steinberg Bruce, Thanos K Panayotis, Downs B William, Siwicki Davis, Lott Lisa, Braverman R Eric, Moran Mark, Miller David, Fried Lyle, Badgaiyan D Rajendra","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We are facing a significant challenge in combatting the current opioid and drug epidemic worldwide. In the USA, although there has been notable progress, in 2017 alone 72,000 people died from a narcotic overdose. The NIAAA & NIDA continue to struggle with innovation to curb or eliminate this unwanted epidemic. The current FDA list of approved Medication Assistance Treatments (MATS) work by primarily blocking dopamine function and release at the pre-neuron in the nucleus accumbens. We oppose this option in the long term tertiary treatment but agree for short term harm reduction potential.</p><p><strong>Bibliography presentation: </strong>As an alternative motif, the utilization of a well-researched neuro-nutrient called KB220 has been intensely investigated in at least 38 studies showing evident effects related to everything from AMA rate, attenuation of craving behavior, reward system activation including BOLD dopamine signaling, relapse prevention, as well as reduction in stress, anger, and aggressive behaviors. We are continuing research especially as it relates to genetic risk, including the now patented Genetic Addiction Risk Score (GARS<sup>®</sup>) and the development of \"Precision Addiction Management (PAM)\" to potentially combat the opioid/psychostimulant epidemic.</p><p><strong>Conclusion: </strong>Based on animal research and clinical trials as presented herein, the Pro-Dopamine Regulator known as KB220 shows promise in the addiction and pain space. Other neurobiological and genetic studies are required to help understand the mechanism of action of this neuro-nutrient. However, the evidence to date points to induction of \"dopamine homeostasis\"enabling an asymptotic approach for epigenetic induced \"normalization\" of brain neurotransmitter signaling and associated improved function in the face of either genetic or epigenetic impairment of the Brain Reward Cascade (BRC).With that said, we are encouraged about these results as published over the last 50 years and look forward to continued advancements related to appropriate nutrigenomic solutions to the millions of victims of all addictions (from drugs to food to smoking to gambling and gaming especially in our next generation) called Reward Surfeit Syndrome (RSS) in adolescents and Reward Deficiency Syndrome (RDS) in adulthood.</p>","PeriodicalId":72715,"journal":{"name":"CPQ neurology and psychology","volume":"1 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448775/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPQ neurology and psychology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/12/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: We are facing a significant challenge in combatting the current opioid and drug epidemic worldwide. In the USA, although there has been notable progress, in 2017 alone 72,000 people died from a narcotic overdose. The NIAAA & NIDA continue to struggle with innovation to curb or eliminate this unwanted epidemic. The current FDA list of approved Medication Assistance Treatments (MATS) work by primarily blocking dopamine function and release at the pre-neuron in the nucleus accumbens. We oppose this option in the long term tertiary treatment but agree for short term harm reduction potential.

Bibliography presentation: As an alternative motif, the utilization of a well-researched neuro-nutrient called KB220 has been intensely investigated in at least 38 studies showing evident effects related to everything from AMA rate, attenuation of craving behavior, reward system activation including BOLD dopamine signaling, relapse prevention, as well as reduction in stress, anger, and aggressive behaviors. We are continuing research especially as it relates to genetic risk, including the now patented Genetic Addiction Risk Score (GARS®) and the development of "Precision Addiction Management (PAM)" to potentially combat the opioid/psychostimulant epidemic.

Conclusion: Based on animal research and clinical trials as presented herein, the Pro-Dopamine Regulator known as KB220 shows promise in the addiction and pain space. Other neurobiological and genetic studies are required to help understand the mechanism of action of this neuro-nutrient. However, the evidence to date points to induction of "dopamine homeostasis"enabling an asymptotic approach for epigenetic induced "normalization" of brain neurotransmitter signaling and associated improved function in the face of either genetic or epigenetic impairment of the Brain Reward Cascade (BRC).With that said, we are encouraged about these results as published over the last 50 years and look forward to continued advancements related to appropriate nutrigenomic solutions to the millions of victims of all addictions (from drugs to food to smoking to gambling and gaming especially in our next generation) called Reward Surfeit Syndrome (RSS) in adolescents and Reward Deficiency Syndrome (RDS) in adulthood.

Abstract Image

前多巴胺调节因子(KB220)对抗奖赏缺乏综合征(RDS)的五十年Sojourn:循证文献(注释)。
背景:我们在应对当前全球阿片类药物和毒品流行方面面临着重大挑战。在美国,尽管取得了显著进展,但仅2017年就有72000人死于麻醉药物过量。NIAA和NIDA继续努力创新,以遏制或消除这种不必要的流行病。美国食品药品监督管理局目前批准的药物辅助治疗(MATS)主要通过阻断伏隔核前神经元的多巴胺功能和释放发挥作用。在长期的三级治疗中,我们反对这种选择,但同意短期减少伤害的潜力。参考文献介绍:作为一种替代主题,至少38项研究对一种名为KB220的经过充分研究的神经营养素的使用进行了深入研究,显示出与AMA率、减少渴望行为、奖励系统激活(包括BOLD多巴胺信号传导)、预防复发以及减轻压力、愤怒、,以及攻击性行为。我们正在继续研究,特别是与遗传风险有关的研究,包括现已获得专利的遗传成瘾风险评分(GARS®)和“精确成瘾管理(PAM)”的开发,以潜在地对抗阿片类药物/精神刺激剂的流行。结论:基于本文所述的动物研究和临床试验,被称为KB220的前多巴胺调节剂在成瘾和疼痛领域显示出了前景。需要进行其他神经生物学和遗传学研究来帮助理解这种神经营养素的作用机制。然而,迄今为止的证据表明,“多巴胺稳态”的诱导为表观遗传学诱导的大脑神经递质信号的“正常化”提供了一种渐进的方法,并在面对大脑奖赏级联(BRC)的遗传或表观遗传学损伤时改善了相关功能,我们对过去50年来发表的这些结果感到鼓舞,并期待着为数百万成瘾(从药物到食物,从吸烟到赌博和游戏,尤其是在我们的下一代)的受害者提供适当的营养基因组解决方案的持续进展,这些成瘾被称为青少年奖励性冲浪综合征(RSS)和成年期
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信